A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

BACKGROUND: Significantly more patients with moderate‐to‐severe plaque psoriasis treated with the interleukin (IL)‐17A inhibitor ixekizumab vs. the IL‐23p19 inhibitor guselkumab in the IXORA‐R head‐to‐head trial achieved 100% improvement in Psoriasis Area and Severity Index (PASI 100) at week 12. OB...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Dermatol
Asıl Yazarlar: Blauvelt, A., Leonardi, C., Elewski, B., Crowley, J.J., Guenther, L.C., Gooderham, M., Langley, R.G., Vender, R., Pinter, A., Griffiths, C.E.M., Tada, Y., Elmaraghy, H., Lima, R.G., Gallo, G., Renda, L., Burge, R., Park, S.Y., Zhu, B., Papp, K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246960/
https://ncbi.nlm.nih.gov/pubmed/32880909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.19509
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller